Accessibility Menu
Cipher Pharmaceuticals logo

Cipher Pharmaceuticals(OTC) CPHRF

Market Cap$308.76MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2012)+825%
5 Year+844%
1 Year+34%
1 Month+3%
$12.06
-0.86%
-0.10Today
Cipher Pharmaceuticals last closing stock price
MetricPriceDate
Last closeUSD 12.162026-08-04
Cipher Pharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+4.29%USD 11.662026-07-28
1 month+3.36%USD 11.772026-07-02
3 month-7.85%USD 13.202026-05-06
Year to date+10.75%USD 10.982025-12-31
1 year+33.63%USD 9.102025-08-04
3 year+352.04%USD 2.692023-08-04
5 year+843.51%USD 1.292021-08-05
Since inception+825.42%USD 1.312012-05-23

Cipher Pharmaceuticals Financials at a Glance

Market Cap

$308.76MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$50.95M

Net Income (TTM)

$30.99M

EPS (TTM)

$1.19

P/E Ratio

10.01

Dividend

$0.00

Beta (Volatility)

0.74 (Low)

Price

$12.06

Volume

393

Open

$12.06

Previous Close

$12.16

Daily Range

$12.06 - $12.06

52-Week Range

$8.92 - $15.00

Estimated Earnings Date

Aug 11, 2026

CPHRF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Cipher Pharmaceuticals

Cipher Pharmaceuticals Inc. is a specialized pharmaceutical company based in Canada, focusing on developing and marketing innovative therapies. The company offers a diverse portfolio of products aimed at addressing various medical conditions, including severe acne and impetigo.

Products and Services
  • Epuris, an isotretinoin formulation for severe acne
  • Ozenoxacin, for managing impetigo in adults and children
  • Actikerall, for treating actinic keratosis
Growth Outlook
  • Development pipeline includes Trevyent for pulmonary arterial hypertension
  • CF-101 is being explored for severe plaque psoriasis and rheumatoid arthritis
  • Strong market demand for innovative dermatological treatments
Financial Highlights
  • Q1 2026 revenue of $12.33 million, showing consistent performance
  • Net income of $6.07 million in Q1 2026, reflecting strong profitability
  • TTM net profit margin of 60.82%, indicating efficient operations
Cipher Pharmaceuticals Inc. operates in the medical pharmaceuticals sector, with a focus on developing specialized treatments. The company has established a strong market presence with its innovative product offerings, which cater to unmet medical needs. The growth outlook is promising, driven by a robust pipeline of new therapies and increasing demand for effective treatments in dermatology and other areas. Recent financial performance highlights the company's ability to generate significant revenue and maintain a strong profit margin, positioning it well for future growth. Investors may find Cipher Pharmaceuticals Inc. an intriguing opportunity within the healthcare sector.
AI Generated • Aug 1, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

61

CEO

Craig Mull

Website

www.cipherpharma.com

Headquarters

Mississauga, ON L4W 0A9, CA

CPHRF Financials

Key Financial Metrics (TTM)

Gross Margin

74.53%

Operating Margin

38.76%

Net Income Margin

60.82%

Return on Equity

25.69%

Return on Capital

12.78%

Return on Assets

20.19%

Earnings Yield

9.99%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$308.76MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

25.39M

Volume

393

Avg. Volume

3.77K

Financials (TTM)

Gross Profit

$37.97M

Operating Income

$19.75M

EBITDA

$25.14M

Operating Cash Flow

$30.11M

Capital Expenditure

-$107.39K

Free Cash Flow

$30.00M

Cash & ST Invst.

$6.43M

Total Debt

$429.41K

Cipher Pharmaceuticals Performance Analysis

Cipher Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 20,675,000-5.8%
20232023-12-31USD 21,162,0002.4%
20242024-12-31USD 33,363,00057.7%
20252025-12-31USD 50,451,00051.2%
Cipher Pharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3011.3%
Q32025-09-30-4.1%
Q42025-12-31-3.3%
Q12026-03-31-0.6%
Cipher Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 1.03257.1%
20232023-12-31USD 0.80-22.3%
20242024-12-31USD 0.46-42.9%
20252025-12-31USD 1.05129.8%
Cipher Pharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30120.0%
Q32025-09-30-4.5%
Q42025-12-31147.6%
Q12026-03-31-53.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$12.33M

+2.6%

Gross Profit

$8.37M

-8.4%

Gross Margin

67.89%

N/A

Market Cap

$308.76MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$51.46M

N/A

Employees

6

N/A

Net Income

$6.08M

+131.6%

EBITDA

$7.30M

+69.9%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$6.43M

-70.8%

Total Debt

$429.41K

-98.9%

Accounts Receivable

$9.78M

-16.9%

Inventory

$8.22M

+48.6%

Long Term Debt

$165.54K

-99.6%

Short Term Debt

$526.86K

-1.3%

Return on Assets

20.19%

N/A

Return on Invested Capital

14.84%

N/A

Free Cash Flow

$4.46M

+5.7%

Operating Cash Flow

$4.46M

+5.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
AONCAmerican Oncology Network, Inc.
$10.00+0.00%
NIKANika Pharmaceuticals Inc.
$0.51+140.23%
ABTIAlterola Biotech, Inc.
$0.00+0.00%
PSIQProfile Solutions, Inc.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$108.96-0.13%
NVDANvidia
$221.65+0.05%
ONDSOndas
$8.88+0.00%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.76-0.04%

Questions About CPHRF

What is the current price of Cipher Pharmaceuticals?

Cipher Pharmaceuticals is trading at $12.06 per share.

What is the 52-week range for Cipher Pharmaceuticals?

Over the past 52 weeks, Cipher Pharmaceuticals has traded between $8.92 and $15.00.

How much debt does Cipher Pharmaceuticals have?

As of the most recent reporting period, Cipher Pharmaceuticals reported total debt of $428.00K.

How much cash does Cipher Pharmaceuticals have on hand?

Cipher Pharmaceuticals reported $6.41M in cash and cash equivalents in its most recent financial results.

What is Cipher Pharmaceuticals’s dividend yield?

Cipher Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services